Low-dose rituximab in adult patients with primary immune thrombocytopenia

European Journal of Haematology

Volumn 85, Issue 4, 2010, Pages 329-334

  Zaja, Francesco ^a   Vianelli, Nicola ^b   Volpetti, Stefano ^a   Battista, Marta Lisa ^a,e   Defina, Marzia ^c   Palmieri, Salvatore ^d   Bocchia, Monica ^c   Medeot, Marta ^a   De Luca, Stefano ^a   Ferrara, Felicetto ^d   Isola, Miriam ^e   Baccarani, Michele ^b   Fanin, Renato ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

Author keywords

B cell depletion; immune thrombocytopenia; rituximab

Indexed keywords

AZATHIOPRINE; CHLORPHENIRAMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; IMMUNOGLOBULIN; PARACETAMOL; RITUXIMAB; STEROID; VINCRISTINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RELAPSE; SALVAGE THERAPY; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; REGRESSION ANALYSIS; REMISSION; THROMBOCYTE COUNT; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; REGRESSION ANALYSIS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77956973924     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01486.x     Document Type: Article

References (18)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 88 : 3 40.
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435 445.
3. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 90 : 2188 2195.
4. Saleh MN, Gutheil J, Moore M. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000 27 (Suppl. 99 103.
5. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 98 : 952 957.
6. Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002 69 : 95 100.
7. Braendstrup P, Pedersen M, Bjerrum OW. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura [abstract]. Blood 2003 102 (Suppl. 298a.
8. Zaja F, Vianelli N, Sperotto A, et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003 88 : 538 546.
9. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125 : 232 239.
10. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, Filì C, Tani M, Baccarani M, Fanin R. Earlier administration of Rituximab allows higher rate of long lasting reponse in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006 34 : 571 572.
11. Peñalver FJ, Jiménez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006 85 : 400 406.
12. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007 86 : 871 877.
13. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 : 25 33.
14. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008 112 : 925 926.
15. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010 115 : 2755 2762.
16. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2008 93 : 930 933.
17. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007 92 : 1695 1698.
18. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007 110 : 2924 2930.